Antengene to Present at ASCO 2024

Antengene Corporation Limited, a prominent biopharmaceutical company, is set to present multiple studies at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The company specializes in groundbreaking treatments for cancer and will showcase one oral presentation, three poster presentations, and a journal publication during the event, which will be held from May 31 to June 4.

Oral Presentation:
Drug: ATG-008 (mTORC1/2 Inhibitor)
Title: Phase I/II study of onatasertib combined with toripalimab in advanced solid tumors: Cervical cancer cohort
Abstract: 5509
Session: Clinical Science Symposium – Stronger Together: Novel Combinations Across the Gynecologic Cancer Spectrum
Date and Time: June 1, 2024, from 1:15 PM to 2:45 PM CDT

A study involving 31 checkpoint inhibitor-naïve cervical cancer patients who had undergone at least one prior line of systemic chemotherapy was conducted. The combination of ATG-008 (onatasertib) and toripalimab (PD-1 antibody) demonstrated a promising overall response rate (ORR) of 53.3% and a disease control rate of 86.7%. The treatment was generally well tolerated, with the most significant adverse events being rash (12.9%), decreased lymphocyte count (9.7%), and decreased platelet count (6.5%).

Poster Presentations:
1. ATG-031 (anti-CD24 monoclonal antibody)
Title: A first-in-human phase I study of ATG-031, anti-CD24 antibody, in advanced solid tumors or B-cell non-Hodgkin lymphomas
Abstract: TPS2691
Session: Developmental Therapeutics—Immunotherapy
Date and Time: June 1, 2024, from 9:00 AM to 12:00 PM CDT

The Phase I PERFORM study aims to assess the safety and preliminary efficacy of ATG-031 in patients with advanced solid tumors or B-cell non-Hodgkin's lymphoma. The drug enhances cancer cell phagocytosis and T cell activity by disrupting the CD24-Siglec-10 interaction on macrophages and induces ADCC and CDC. The study is currently ongoing in four U.S. sites.

2. ATG-022 (Claudin 18.2 Antibody-drug Conjugate)
Title: An open-label, multicenter, phase I study of ATG-022 in advanced/metastatic solid tumors
Abstract: 3032
Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Date and Time: June 1, 2024, from 9:00 AM to 12:00 PM CDT

The CLINCH Phase I trial evaluates the safety, tolerability, and efficacy of ATG-022 in patients with advanced/metastatic solid tumors. The drug showed substantial tumor inhibition in preclinical studies. Ten patients have been enrolled so far, with doses ranging from 0.3 to 2.4 mg/kg. Preliminary results show one complete response and one partial response in gastric cancer patients. The drug appears to be well-tolerated, with no dose-limiting toxicities reported.

3. Selinexor (XPO1 Inhibitor)
Title: Selinexor combined with tislelizumab in relapsed/refractory extranodal NK/T-cell lymphoma (R/R ENKTL): Results of cohort C from phase I/II study
Abstract: 7065
Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Date and Time: June 3, 2024, from 9:00 AM to 12:00 PM CDT

The Phase I/II TOUCH study examines selinexor combined with tislelizumab in R/R ENKTL patients. Twelve patients have been enrolled with no observed dose-limiting toxicities. The combination has shown an ORR of 72.7%, with a CR rate of 36.4%, indicating a promising efficacy and a manageable safety profile.

Journal Publication:
Drug: ATG-017 (ERK1/2 Inhibitor)
Title: First-in-human, dose-escalation phase I study of ATG-017 in advanced solid tumors
Abstract: e15114

Published findings on ATG-017, an oral ERK1/2 inhibitor, highlight its safety and pharmacokinetics in patients with refractory advanced solid tumors. No dose-limiting toxicities were observed at the 20 mg BID level. One patient achieved a partial response, and 38% of patients experienced stable disease.

Antengene continues to expand its oncology pipeline, aiming to develop innovative treatments for hematologic malignancies and solid tumors, aligning with its mission of treating patients worldwide.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!